LH02

General Information


DRACP ID  DRACP01784

Peptide Name   LH02

Sequence  RRRRRRRRVKLVNLGFATLREHVP

Sequence Length  24

UniProt ID  Q06234  Q02067  P19359  P50553 

PubChem CID  Not available

Origin  Synthetics

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
NCI-H82 Lung small cell carcinoma; Small cell lung cancer Carcinoma EC50≈7 μM MTT assay Not available Patent
NCI-H187 Lung small cell carcinoma; Small cell lung cancer Carcinoma EC50≈10 μM MTT assay Not available Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01784

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C131H233N55O29

Absent amino acids  CDIMQSWY

Common amino acids  R

Mass  345304

Pl  13.05

Basic residues  11

Acidic residues  1

Hydrophobic residues  8

Net charge  10

Boman Index  -12790

Hydrophobicity  -119.58

Aliphatic Index  89.17

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US2020/0157150A1

Patent Title  Anticancer Peptides

Other Iinformation  Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017

Other Published ID  AU2018311129A1  CA3071601A1  CN111436200A  EP3661947A1  JP2020529429A  KR20200032730A  WO2019025432A1 




DRACP is developed by Dr.Zheng's team.